A Randomized Study of Nivolumab with Ipilimumab or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1/L1 Agent (S1616)
A Randomized Study of Nivolumab with Ipilimumab or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1/L1 Agent (S1616)
Trial Category:
Melanoma
Phase
II
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
